StrokeNCT03874702
Automated Diagnosis of Stroke in Computed Tomography With the Use of Artificial Intelligence
An observational study of Stroke and Ischemic Stroke, run by University of Guadalajara at 1 site in Mexico.
Trial summary
The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Ischemic Stroke
- How many people
- 350 participants
- Where
- 1 siteMexico
- Study dates
- 15 Aug 2019to 1 Jun 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: adult patients with ischemic stroke diagnosis, within the <4.5 hrs. window after the onset of the symptoms
Who may be able to join
- Patients with ischemic stroke.
- Patients with <4.5 hours of symptom onset.
Who cannot join
- Patients with hemorrhagic stroke diagnosis.
- Patients with other cerebrovascular diseases.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assisted Method for the Quantification, Localization and Automated Diagnosis of Stroke in Computed Tomography With the Use of Artificial Intelligence
The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized health personnel for the attention of this disease.
Read the detailed description
PROBLEM STATEMENT Stroke is the fifth cause of death in the United States and the number one cause of long term disability. Annually around 800,000 persons are diagnosed with stroke in this country, causing the death of around 130,000 persons, each 4 minutes one person die due to this disease in the U.S.A.
In Mexico there is very few statistical information published about stroke, according to the Mexican clinical practice guidelines "CENETEC" this disease was the third cause of death, with the 5.6% percent of the main death causes, with an estimated rate of 25.6/100,000 habitants and more than 25,000 deaths per year according to data of the health department.
The monetary cost of the direct attention and the indirect expenses is enormous, with an approximate expenditure of 34 billion dollars per year. Around 20% of the survivors require special care during the first 3 months after a stroke event and around 30% remain with a severe disability.
In Mexico there is an alarming increase of stroke cases that correlates with the demographic transition to an older population, and also to the increase of risk factors for vascular atherothrombotic disease, as the hypertension, diabetes, obesity and dyslipidemia.
Local statistics show that from the different type of stroke the distribution in Mexico is: 72.94% as ischemic stroke, 20.17% hemorrhagic and 6.8% with subarachnoid hemorrhage, this numbers are similar to the statistic reported in the literature of other countries.
According to the first multicentric registry in Mexico "The Premier Study" the distribution of the etiology of the ischemic stroke was: large vessel atherosclerosis 8%, cardiac embolism 20%, lacunar stroke 20% , miscellaneous 5% and undetermined etiology 41%. In Mexico only 0.6% of the patients with stroke are treated with I.V. thrombolysis, and of these patients, 33% arrived in a window <3 hrs. after the onset of the stroke.
JUSTIFICATION
The medical care and diagnosis of the patients with stroke is considered a medical emergency, studies have reported the denominated "Time is brain" due to the fact, that patients with a typical large vessel ischemic stroke, each minute 1.9 million neurons, 14 billion of synapsis and around 12 km. of myelinated fibers are lost, this remark the need of an early diagnosis and treatment.
According to "The Premier Study" one of the most concerning outcomes in the medical care of stroke in Mexico is that only a fifth of the patients with stroke arrive to the hospital within the window for I.V. thrombolysis, and of them < 1% receive treatment with rTPA. This is due to factors as the lack of specialized medical teams for an opportune and precise diagnosis, a limited number of staff with expertise in stroke and a lack of technological resources for diagnosis.
Fort he particular case of the stroke, there are several characteristics that propitiate the use of artificial intelligence (A.I.) systems, some of them are the great quantity of data and multidisciplinary approaches used for the medical decision making, particularly the use of imaging studies, due to the fact that this are key factors in the stroke management.
Other factors that have contributed for the use of A.I. in stroke are the lack of experts for the imaging diagnosis, this problem is clearly exacerbated in developing countries. Only a few hospitals have access to specialized neuroradiologists or neurologist to provide an opportune and optimal diagnosis, this generates a delay or even an inaccurate diagnosis.
There is even a variable concordance ranging up to 39% between specialized physicians for the diagnosis of stroke in non-contrasted computed tomography in the medial cerebral artery territory, this demonstrate the great inter-reader variability, furthermore there is sparse definition of the characteristics of early infarct, demonstrating the need for a standardized method of stroke imaging.
Several studies have demonstrated the efficacy of the A.I. systems in the stroke diagnosis, most of them show that the automatized diagnosis with the A.I. is in the majority of the times the same or even better than the manual segmentation with human diagnosis by stroke experts.
There is even a stroke evaluation system already in the market, based on A.I. algorithms, this has already demonstrated its utility in the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), "The Electronic-Alberta Stroke Program Early Computed Tomography Score Software.
BACKGROUNDS
The A.I. has been defined as the study of the computations that make possible to perceive, think and act. A.I. systems have focused to emulate the cognitive functions of the humans, due to the rapidly advances in the computational sciences the A.I. is being used in multiple fields, especially in big companies of information technology as google.
The precision medicine has been defined as the personalized diagnosis and treatment of an individual patient, this is an emerging concept in the contemporary medicine. The great number of information generated in biology, immunology, genomics and the advances in the imaging technology has created the path to this personalized medicine.
These advances have generated a transition in the modern healthcare models, propelled by the great quantity of data and the advance of the analytic techniques. Guided by relevant clinical questions, the A.I. systems can reveal valuable information hided within massive amounts of data (big data), due to its analytic qualities. This can be helpful in the clinical decision making.
Currently there are companies as I.B.M. and it's A.I. system Watson for Oncology (WFO), developing Clinical Decision-Support Systems (CDSSs) in collaboration with hospitals as the Memorial Sloan Kettering Cancer Center, this system pretends to help oncology specialist with the current challenges of the great amount of data in fields as genetics, pharmacology and treatment guidelines, analyzing big data bases for a more personalized treatment of the patient. WFO was tested with real cases discussed in the multidisciplinary boards at the Memorial Sloan Kettering Cancer Center obtaining a great level of concordance in their series, and currently is already available in the market.
HYPOTHESIS
The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized health personnel for the attention of this disease.
OBJECTIVES
General Objective
- Design an A.I. algorithm for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, base in a hybrid model with the use of machine learning and statistic modeling, evaluated its efficacy and create a software for the assistance of medical decision making.
Specific objectives
- Standardize the data collection and the creation of data banks of non-contrasted head computed tomography with ischemic stroke diagnosis for the inclusion into the A.I.
- Create non-contrasted head computed tomography data bases with representative samples of the different types of ischemic stroke, considering the multiple anatomical distributions, sizes and evolution phases.
- Standardize an image segmentation method, location of the lesion, diagnosis and ASPECT (Alberta Stroke Programme Early CT Score) scoring.
- Generate an efficient software for the assistance of clinical decision making to non-specialized medical staff in the diagnosis of this disease, in order to expedite the medical care of this population of patients in places, where a lack of specialized teams and technologic resources exists, for the diagnosis of this disease.
Technical Objectives
- Standardize the collection of the anonymized non-contrasted head computed tomography DICOM files with their respective system specifications (headers) for the creation of the "Ground Truth" of the machine learning system.
- Create an efficient algorithm and evaluate its accuracy in the stroke diagnosis through several pre-clinical tests with expert specialized physicians in cerebrovascular disease.
- Design an interactive software and easy to use for the medical staff, for fast a clinical decision making and with support on evidence-based medicine for patients with suspicion of ischemic stroke.
GOALS
- Create a software for the quantification, location and automatized diagnosis of stroke , that is efficient and accurate for the clinical decision making in the absence of specialized medical staff and technological resources for the medical care of patients with stroke.
- Obtain the register of a patent of the machine learning based software.
- Generate the publication of multiple articles in international journals.
METHODOLOGY
Type of study
Observational prospective study, descriptive, without patient intervention, without blinding for the analysis of the non-contrasted head computed tomography and its clinical correlation.
In the present study the confidentiality of the patient will be maintained, as the investigators won't need the identification data from the patients.
In the present study the investigators pretend to create a hybrid A.I. model using a combined method of statistic modeling for the first prototype of the algorithm and then continue with the creation of the machine learning algorithm, combining both algorithms for a better accuracy and efficacy.
For the first algorithm with statistic modeling the investigators pretend to obtain a representative sample with the different types of ischemic stroke, until the investigators collect 50 images, clinical information and its respective diagnosis and ASPECT score.
Continuing with the prospective creation of a data base of computed tomography imaging, clinical correlation, and their respective diagnosis and ASPECT score for the feeding of the machine learning algorithm, that usually requires large quantities of data for its training.
For both algorithms the investigators pretend to test them with independent evaluators, whose expertise will be on cerebrovascular disease, and the investigators will compare de results of the A.I. system with the diagnosis of the specialized evaluators, in order to calibrate the cut off points of the algorithm to obtain the maximal concordance .
INFRASTRUCTURE
For the developing of this protocol the investigators pretend to use the facilities of the Department of Neurosciences form the Health Sciences Center of the University of Guadalajara "CUCS". The collection of the images will be done in collaboration with the Department of radiology of the "Hospital Civil de Guadalajara, Fray Antonio Alcalde" and "Hospital Civil de Guadalajara, Juan I. Menchaca".
The evaluation of the images will be performed in collaboration with the Neurology Department of the "Hospital Civil de Guadalajara, Fray Antonio Alcalde".
The creation of the A.I. algorithm will be done in collaboration with the University Center of Engineering and Exact Sciences (CUCEI) from the University of Guadalajara, in the department of computational sciences from CUCEI.
- Conditions
- Stroke, Ischemic Stroke
- Keywords
- stroke, artificial intelligence, ischemic stroke
- Medical subject headings
- Stroke, Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ischemic stroke patients with <4.5 hours of onset . | analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alberta Stroke Program Early Computed Tomography Score
The Alberta stroke programme early CT score (ASPECTS) 1 is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery stroke. It has also been adapted for the posterior circulation.
Scoring system
Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved:
caudate putamen internal capsule insular cortex M1: "anterior MCA cortex," corresponding to frontal operculum M2: "MCA cortex lateral to insular ribbon" corresponding to anterior temporal lobe M3: "posterior MCA cortex" corresponding to posterior temporal lobe M4: "anterior MCA territory immediately superior to M1" M5: "lateral MCA territory immediately superior to M2" M6: "posterior MCA territory immediately superior to M3"
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2019
- Study start15 Aug 2019
- Primary completion1 Jun 2025 (estimated)
- Study completion1 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 350 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University of Guadalajara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ivan Segura Duran, University of Guadalajara
- Investigators
- Rodrigo Ramos Zúñiga, M.D. Ph.D., Principal investigator, University of GuadalajaraEduardo Gerardo Mendizábal Ruiz, Ph.D., Principal investigator, University of GuadalajaraJosé Luis Ruiz Sandoval, M.D., Principal investigator, University of GuadalajaraIvan Segura Duran, M.D., Study chair, University of Guadalajara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03874702
- Sponsor's protocol ID
- UGuadalajara
- Status last verified
- May 2021
- First submitted
- 12 Mar 2019
- Last updated
- 18 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17. No abstract available.
PubMed 25520374Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. No abstract available.
PubMed 28122885Saver JL. Time is brain--quantified. Stroke. 2006 Jan;37(1):263-6. doi: 10.1161/01.STR.0000196957.55928.ab. Epub 2005 Dec 8.
PubMed 16339467Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke. 1999 Aug;30(8):1528-33. doi: 10.1161/01.str.30.8.1528.
PubMed 10436095Mullins ME, Lev MH, Schellingerhout D, Koroshetz WJ, Gonzalez RG. Influence of availability of clinical history on detection of early stroke using unenhanced CT and diffusion-weighted MR imaging. AJR Am J Roentgenol. 2002 Jul;179(1):223-8. doi: 10.2214/ajr.179.1.1790223.
PubMed 12076941Nagel S, Wang X, Carcel C, Robinson T, Lindley RI, Chalmers J, Anderson CS; ENCHANTED Investigators. Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. Stroke. 2018 Jun;49(6):1407-1411. doi: 10.1161/STROKEAHA.117.019863. Epub 2018 May 18.
PubMed 29777016Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017 Jun 21;2(4):230-243. doi: 10.1136/svn-2017-000101. eCollection 2017 Dec.
PubMed 29507784Somashekhar SP, Sepulveda MJ, Puglielli S, Norden AD, Shortliffe EH, Rohit Kumar C, Rauthan A, Arun Kumar N, Patil P, Rhee K, Ramya Y. Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol. 2018 Feb 1;29(2):418-423. doi: 10.1093/annonc/mdx781.
PubMed 29324970Cantu-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, Chiquete E, Leon-Jimenez C, Arauz A, Villarreal-Careaga J, Barinagarrementeria F, Ramos-Moreno A; PREMIER Investigators. The first Mexican multicenter register on ischaemic stroke (the PREMIER study): demographics, risk factors and outcome. Int J Stroke. 2011 Feb;6(1):93-4. doi: 10.1111/j.1747-4949.2010.00549.x. No abstract available.
PubMed 21205252Cantu-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, Chiquete E, Leon-Jimenez C, Arauz A, Villarreal-Careaga J, Rangel-Guerra R, Ramos-Moreno A, Barinagarrementeria F; PREMIER Investigators. Acute care and one-year outcome of Mexican patients with first-ever acute ischemic stroke: the PREMIER study. Rev Neurol. 2010 Dec 1;51(11):641-9. English, Spanish.
PubMed 21108226Lee EJ, Kim YH, Kim N, Kang DW. Deep into the Brain: Artificial Intelligence in Stroke Imaging. J Stroke. 2017 Sep;19(3):277-285. doi: 10.5853/jos.2017.02054. Epub 2017 Sep 29.
PubMed 29037014
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assisted Method for the Quantification, Localization and Automated Diagnosis of Stroke in Computed Tomography With the Use of Artificial Intelligence
- ClinicalTrials.gov ID
- NCT03874702
- Acronym / sponsor ID
- UGuadalajara
- Conditions
- Stroke, Ischemic Stroke
- Keywords
- stroke, artificial intelligence, ischemic stroke
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 350 participants (estimated)
- Lead sponsor
- University of GuadalajaraUniversity, hospital or other
- Study start
- 15 Aug 2019 (actual)
- Primary completion
- 1 Jun 2025 (estimated)
- Study completion
- 1 Jun 2025 (estimated)
- First posted
- 14 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized health personnel for the attention of this disease.
Detailed description
PROBLEM STATEMENT Stroke is the fifth cause of death in the United States and the number one cause of long term disability. Annually around 800,000 persons are diagnosed with stroke in this country, causing the death of around 130,000 persons, each 4 minutes one person die due to this disease in the U.S.A.
In Mexico there is very few statistical information published about stroke, according to the Mexican clinical practice guidelines "CENETEC" this disease was the third cause of death, with the 5.6% percent of the main death causes, with an estimated rate of 25.6/100,000 habitants and more than 25,000 deaths per year according to data of the health department.
The monetary cost of the direct attention and the indirect expenses is enormous, with an approximate expenditure of 34 billion dollars per year. Around 20% of the survivors require special care during the first 3 months after a stroke event and around 30% remain with a severe disability.
In Mexico there is an alarming increase of stroke cases that correlates with the demographic transition to an older population, and also to the increase of risk factors for vascular atherothrombotic disease, as the hypertension, diabetes, obesity and dyslipidemia.
Local statistics show that from the different type of stroke the distribution in Mexico is: 72.94% as ischemic stroke, 20.17% hemorrhagic and 6.8% with subarachnoid hemorrhage, this numbers are similar to the statistic reported in the literature of other countries.
According to the first multicentric registry in Mexico "The Premier Study" the distribution of the etiology of the ischemic stroke was: large vessel atherosclerosis 8%, cardiac embolism 20%, lacunar stroke 20% , miscellaneous 5% and undetermined etiology 41%. In Mexico only 0.6% of the patients with stroke are treated with I.V. thrombolysis, and of these patients, 33% arrived in a window <3 hrs. after the onset of the stroke.
JUSTIFICATION
The medical care and diagnosis of the patients with stroke is considered a medical emergency, studies have reported the denominated "Time is brain" due to the fact, that patients with a typical large vessel ischemic stroke, each minute 1.9 million neurons, 14 billion of synapsis and around 12 km. of myelinated fibers are lost, this remark the need of an early diagnosis and treatment.
According to "The Premier Study" one of the most concerning outcomes in the medical care of stroke in Mexico is that only a fifth of the patients with stroke arrive to the hospital within the window for I.V. thrombolysis, and of them < 1% receive treatment with rTPA. This is due to factors as the lack of specialized medical teams for an opportune and precise diagnosis, a limited number of staff with expertise in stroke and a lack of technological resources for diagnosis.
Fort he particular case of the stroke, there are several characteristics that propitiate the use of artificial intelligence (A.I.) systems, some of them are the great quantity of data and multidisciplinary approaches used for the medical decision making, particularly the use of imaging studies, due to the fact that this are key factors in the stroke management.
Other factors that have contributed for the use of A.I. in stroke are the lack of experts for the imaging diagnosis, this problem is clearly exacerbated in developing countries. Only a few hospitals have access to specialized neuroradiologists or neurologist to provide an opportune and optimal diagnosis, this generates a delay or even an inaccurate diagnosis.
There is even a variable concordance ranging up to 39% between specialized physicians for the diagnosis of stroke in non-contrasted computed tomography in the medial cerebral artery territory, this demonstrate the great inter-reader variability, furthermore there is sparse definition of the characteristics of early infarct, demonstrating the need for a standardized method of stroke imaging.
Several studies have demonstrated the efficacy of the A.I. systems in the stroke diagnosis, most of them show that the automatized diagnosis with the A.I. is in the majority of the times the same or even better than the manual segmentation with human diagnosis by stroke experts.
There is even a stroke evaluation system already in the market, based on A.I. algorithms, this has already demonstrated its utility in the ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), "The Electronic-Alberta Stroke Program Early Computed Tomography Score Software.
BACKGROUNDS
The A.I. has been defined as the study of the computations that make possible to perceive, think and act. A.I. systems have focused to emulate the cognitive functions of the humans, due to the rapidly advances in the computational sciences the A.I. is being used in multiple fields, especially in big companies of information technology as google.
The precision medicine has been defined as the personalized diagnosis and treatment of an individual patient, this is an emerging concept in the contemporary medicine. The great number of information generated in biology, immunology, genomics and the advances in the imaging technology has created the path to this personalized medicine.
These advances have generated a transition in the modern healthcare models, propelled by the great quantity of data and the advance of the analytic techniques. Guided by relevant clinical questions, the A.I. systems can reveal valuable information hided within massive amounts of data (big data), due to its analytic qualities. This can be helpful in the clinical decision making.
Currently there are companies as I.B.M. and it's A.I. system Watson for Oncology (WFO), developing Clinical Decision-Support Systems (CDSSs) in collaboration with hospitals as the Memorial Sloan Kettering Cancer Center, this system pretends to help oncology specialist with the current challenges of the great amount of data in fields as genetics, pharmacology and treatment guidelines, analyzing big data bases for a more personalized treatment of the patient. WFO was tested with real cases discussed in the multidisciplinary boards at the Memorial Sloan Kettering Cancer Center obtaining a great level of concordance in their series, and currently is already available in the market.
HYPOTHESIS
The use of the systems of machine learning for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, is a method with high efficacy, accessible and susceptible for standardization, for the assistance in the clinical decision making in the absence of specialized health personnel for the attention of this disease.
OBJECTIVES
General Objective
- Design an A.I. algorithm for the quantification, location and diagnosis of ischemic stroke in non-contrasted head computed tomography, base in a hybrid model with the use of machine learning and statistic modeling, evaluated its efficacy and create a software for the assistance of medical decision making.
Specific objectives
- Standardize the data collection and the creation of data banks of non-contrasted head computed tomography with ischemic stroke diagnosis for the inclusion into the A.I.
- Create non-contrasted head computed tomography data bases with representative samples of the different types of ischemic stroke, considering the multiple anatomical distributions, sizes and evolution phases.
- Standardize an image segmentation method, location of the lesion, diagnosis and ASPECT (Alberta Stroke Programme Early CT Score) scoring.
- Generate an efficient software for the assistance of clinical decision making to non-specialized medical staff in the diagnosis of this disease, in order to expedite the medical care of this population of patients in places, where a lack of specialized teams and technologic resources exists, for the diagnosis of this disease.
Technical Objectives
- Standardize the collection of the anonymized non-contrasted head computed tomography DICOM files with their respective system specifications (headers) for the creation of the "Ground Truth" of the machine learning system.
- Create an efficient algorithm and evaluate its accuracy in the stroke diagnosis through several pre-clinical tests with expert specialized physicians in cerebrovascular disease.
- Design an interactive software and easy to use for the medical staff, for fast a clinical decision making and with support on evidence-based medicine for patients with suspicion of ischemic stroke.
GOALS
- Create a software for the quantification, location and automatized diagnosis of stroke , that is efficient and accurate for the clinical decision making in the absence of specialized medical staff and technological resources for the medical care of patients with stroke.
- Obtain the register of a patent of the machine learning based software.
- Generate the publication of multiple articles in international journals.
METHODOLOGY
Type of study
Observational prospective study, descriptive, without patient intervention, without blinding for the analysis of the non-contrasted head computed tomography and its clinical correlation.
In the present study the confidentiality of the patient will be maintained, as the investigators won't need the identification data from the patients.
In the present study the investigators pretend to create a hybrid A.I. model using a combined method of statistic modeling for the first prototype of the algorithm and then continue with the creation of the machine learning algorithm, combining both algorithms for a better accuracy and efficacy.
For the first algorithm with statistic modeling the investigators pretend to obtain a representative sample with the different types of ischemic stroke, until the investigators collect 50 images, clinical information and its respective diagnosis and ASPECT score.
Continuing with the prospective creation of a data base of computed tomography imaging, clinical correlation, and their respective diagnosis and ASPECT score for the feeding of the machine learning algorithm, that usually requires large quantities of data for its training.
For both algorithms the investigators pretend to test them with independent evaluators, whose expertise will be on cerebrovascular disease, and the investigators will compare de results of the A.I. system with the diagnosis of the specialized evaluators, in order to calibrate the cut off points of the algorithm to obtain the maximal concordance .
INFRASTRUCTURE
For the developing of this protocol the investigators pretend to use the facilities of the Department of Neurosciences form the Health Sciences Center of the University of Guadalajara "CUCS". The collection of the images will be done in collaboration with the Department of radiology of the "Hospital Civil de Guadalajara, Fray Antonio Alcalde" and "Hospital Civil de Guadalajara, Juan I. Menchaca".
The evaluation of the images will be performed in collaboration with the Neurology Department of the "Hospital Civil de Guadalajara, Fray Antonio Alcalde".
The creation of the A.I. algorithm will be done in collaboration with the University Center of Engineering and Exact Sciences (CUCEI) from the University of Guadalajara, in the department of computational sciences from CUCEI.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ischemic stroke patients with <4.5 hours of onset . | – | –analysis of the computed tomography without contrast and detection of early changes, scoring with ASPECTS score and integration to the machine learning data base. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- adult patients with ischemic stroke diagnosis, within the <4.5 hrs. window after the onset of the symptoms
Key inclusion criteria (2 listed)
- Patients with ischemic stroke.
- Patients with <4.5 hours of symptom onset.
Key exclusion criteria (2 listed)
- Patients with hemorrhagic stroke diagnosis.
- Patients with other cerebrovascular diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Alberta Stroke Program Early Computed Tomography Score
Time frame: 1 day
The Alberta stroke programme early CT score (ASPECTS) 1 is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery stroke. It has also been adapted for the posterior circulation. Scoring system Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved: caudate putamen internal capsule insular cortex M1: "anterior MCA cortex," corresponding to frontal operculum M2: "MCA cortex lateral to insular ribbon" corresponding to anterior temporal lobe M3: "posterior MCA cortex" corresponding to posterior temporal lobe M4: "anterior MCA territory immediately superior to M1" M5: "lateral MCA territory immediately superior to M2" M6: "posterior MCA territory immediately superior to M3"
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2021.
- Background: PubMed 25520374Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17. No abstract available.
- Background: PubMed 28122885Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. No abstract available.
- Background: PubMed 16339467Saver JL. Time is brain--quantified. Stroke. 2006 Jan;37(1):263-6. doi: 10.1161/01.STR.0000196957.55928.ab. Epub 2005 Dec 8.
- Background: PubMed 10436095Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke. 1999 Aug;30(8):1528-33. doi: 10.1161/01.str.30.8.1528.
- Background: PubMed 12076941Mullins ME, Lev MH, Schellingerhout D, Koroshetz WJ, Gonzalez RG. Influence of availability of clinical history on detection of early stroke using unenhanced CT and diffusion-weighted MR imaging. AJR Am J Roentgenol. 2002 Jul;179(1):223-8. doi: 10.2214/ajr.179.1.1790223.
- Background: PubMed 29777016Nagel S, Wang X, Carcel C, Robinson T, Lindley RI, Chalmers J, Anderson CS; ENCHANTED Investigators. Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. Stroke. 2018 Jun;49(6):1407-1411. doi: 10.1161/STROKEAHA.117.019863. Epub 2018 May 18.
- Background: PubMed 29507784Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017 Jun 21;2(4):230-243. doi: 10.1136/svn-2017-000101. eCollection 2017 Dec.
- Background: PubMed 29324970Somashekhar SP, Sepulveda MJ, Puglielli S, Norden AD, Shortliffe EH, Rohit Kumar C, Rauthan A, Arun Kumar N, Patil P, Rhee K, Ramya Y. Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board. Ann Oncol. 2018 Feb 1;29(2):418-423. doi: 10.1093/annonc/mdx781.
- Results publication: PubMed 21205252Cantu-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, Chiquete E, Leon-Jimenez C, Arauz A, Villarreal-Careaga J, Barinagarrementeria F, Ramos-Moreno A; PREMIER Investigators. The first Mexican multicenter register on ischaemic stroke (the PREMIER study): demographics, risk factors and outcome. Int J Stroke. 2011 Feb;6(1):93-4. doi: 10.1111/j.1747-4949.2010.00549.x. No abstract available.
- Results publication: PubMed 21108226Cantu-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, Chiquete E, Leon-Jimenez C, Arauz A, Villarreal-Careaga J, Rangel-Guerra R, Ramos-Moreno A, Barinagarrementeria F; PREMIER Investigators. Acute care and one-year outcome of Mexican patients with first-ever acute ischemic stroke: the PREMIER study. Rev Neurol. 2010 Dec 1;51(11):641-9. English, Spanish.
- Results publication: PubMed 29037014Lee EJ, Kim YH, Kim N, Kang DW. Deep into the Brain: Artificial Intelligence in Stroke Imaging. J Stroke. 2017 Sep;19(3):277-285. doi: 10.5853/jos.2017.02054. Epub 2017 Sep 29.
- website of our institute of traslational neurosciencesLink provided by the sponsor.
- website of our centerLink provided by the sponsor.
- website of our hospital facilitiesLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rodrigo Ramos Zúñiga, M.D. Ph.D. principal investigator
University of Guadalajara
Eduardo Gerardo Mendizábal Ruiz, Ph.D. principal investigator
University of Guadalajara
José Luis Ruiz Sandoval, M.D. principal investigator
University of Guadalajara
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke and Ischemic Stroke, run by University of Guadalajara at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alberta Stroke Program Early Computed Tomography Score (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03874702, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2021.